In addition to the application of oral medications, is there currently a procedure that can also achieve the effect of stroke prevention? According to Prof. Li Yigang of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, although catheter ablation has now become the first-line treatment for symptomatic atrial fibrillation in which drugs are ineffective, its success rate is poor, especially in terms of long-term outcome. Therefore, warfarin remains the main antithrombotic treatment for clinical AF, but the narrow safety window of warfarin therapy and the need for frequent monitoring of coagulation function have led to poor compliance with the drug. Newer anticoagulants such as dabigatran have been used in a rather limited population due to their high price and uncertain long-term efficacy and side effects. It should be noted that the majority of patients at high risk for embolism are also at high risk for bleeding, and approximately 14% to 44% of patients are unable to receive long-term pharmacologic anticoagulation because of contraindications. More than 90% of thrombi in patients with non-valvular AF originate from the left auricle, so it is clearly justified to prevent thrombosis by resection or blocking the left auricle. The results of a series of clinical studies, as represented by the PROTECT-AF trial, have led the mainstream opinion to agree that the clear success criteria and reliable long-term efficacy of left auricular occlusion itself are clearly of special interest to physicians involved in atrial fibrillation interventions in patients with atrial fibrillation who are at high risk of stroke, when traditional or new anticoagulation therapies are not available or have problems such as side effects. We can expect that the use of left-ear occlusion will rapidly spread in China as several relevant occlusion devices receive clinical application licenses from the CFDA. What is the current status of the use of left ear occlusion procedures? Based on the increasing effectiveness and safety of left-ear occlusion devices, left-ear occlusion for stroke prevention in high-risk atrial fibrillation patients with contraindications to anticoagulation has been included for the first time in the ESC guidelines for the treatment of atrial fibrillation (Class IIb recommendation, Level B evidence). From the current practice and clinical studies, Director Li Yigang believes that with the advancement of left ear occlusion devices and the accumulation of experience, left ear occlusion can be one of the important supplements to pharmacological therapy for the prevention of AF embolic events, especially for patients with contraindications to anticoagulant medications and those of advanced age and high bleeding risk.